Venlafaxine for Generalized Social Anxiety Disorder

Monoamine oxidase inhibitors, SSRIs, and group cognitive-behavioral therapy have each obtained response rates of 50% to 60% in patients with social anxiety disorder. However, considerably . . .

Monoamine oxidase inhibitors, SSRIs, and group cognitive-behavioral therapy have each obtained response rates of 50% to 60% in patients with social anxiety disorder. However, considerably fewer patients achieve remission, indicating a need for novel treatments. These investigators conducted a manufacturer-sponsored, double-blind, randomized, placebo-controlled trial of the dual serotonin-norepinephrine reuptake inhibitor venlafaxine in the treatment of generalized social anxiety disorder (GSAD).

Researchers evaluated 364 nondepressed patients with GSAD (mean duration of illness, about 20 years) who received placebo, a fixed dose of extended-release venlafaxine (75 mg/day), or a flexible dose of extended-release venlafaxine (150-225 mg/day) f…

Reviewing Author

Deborah Cowley, MD